Synthorx to Present at H.C. Wainwright Global Life Sciences Conference in London
April 02 2019 - 8:00AM
Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a
first-of-its-kind Expanded Genetic Alphabet platform technology to
discover and develop optimized biologics for cancer and autoimmune
disorders, today announced that management will present at the H.C.
Wainwright Global Life Sciences Conference held in London, UK. The
presentation will begin at 9:10 a.m. BST (1:10 a.m. PDT) on Monday,
April 8, 2019.
The live webcast of the company’s presentation will be available
at Synthorx’s investor relations website. An archived replay
will be available for 30 days following the presentation.
About Synthorx Synthorx, Inc. is a
biotechnology company focused on prolonging and improving the lives
of people with cancer and autoimmune disorders. Synthorx’s
proprietary, first-of-its-kind Expanded Genetic Alphabet platform
technology expands the genetic code by adding a new DNA base pair
and is designed to create optimized biologics, referred to as
Synthorins. A Synthorin is a protein optimized through
incorporation of novel amino acids encoded by the new DNA base pair
that enables site-specific modifications, which enhance the
pharmacological properties of these therapeutics. The company’s
lead product candidate, THOR-707, a variant of IL-2, is in
development in multiple tumor types as a single agent and in
combination with an immune checkpoint inhibitor. The company was
founded based on important discoveries in Dr. Floyd Romesberg’s lab
at The Scripps Research Institute. The company is headquartered in
La Jolla, Calif. For more information, visit www.synthorx.com.
Forward-Looking Statements This press release
contains forward-looking statements about Synthorx as that term is
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Statements in this
press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other
things, the expected ability of Synthorx to undertake certain
activities and accomplish certain goals and objectives. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, risks associated with the process of discovering,
developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a
business around such drugs. These forward-looking statements are
made as of the date of this press release, and Synthorx assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements. Investors should consult all of the
information set forth herein and should also refer to the risk
factor disclosure set forth in the reports and other documents the
company files with the Securities and Exchange Commission available
at www.sec.gov, including without limitation Synthorx’s Annual
Report on Form 10-K for the year ended December 31, 2018 as well as
Synthorx’s subsequent filings with the SEC.
Investor Contacts: Enoch Kariuki,
Pharm.D.Synthorx, Inc.ekariuki@synthorx.com 858-750-4750
Christina TartagliaStern Investor
Relationschristina.tartaglia@sternir.com212-362-1200
Media Relations Contact:Lauren FishCanale
Communicationslauren@canalecomm.com619-849-5386
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Sep 2023 to Sep 2024